CRBU

In the past six months, Caribou Biosciences' stock has been impacted by several events. The Q2 2026 earnings report on August 13, 2026, showed a quarterly loss of ($0.24) EPS, which exceeded analyst estimates, but revenue of $1.50 million fell short of expectations. Analyst ratings saw Bank of America cut its price objective from $6.00 to $5.00 while maintaining a "buy" rating, Weiss Ratings reiterated a "sell (d-)" rating, and Wall Street Zen downgraded the stock to a "sell" rating; however, the consensus from five analysts remains a "Moderate Buy" with an average 1-year target price of $7.75. Clinical data presentations on June 11, 2026, at the EHA 2026 Congress included positive long-term data for vispa-cel (CB-010) in second-line large B cell lymphoma, showing an 82% overall response rate and 67% complete response rate, and dose escalation durability data for CB-011 in relapsed or refractory multiple myeloma, demonstrating deep, durable responses. On March 31, 2026, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011 for relapsed or refractory multiple myeloma following promising Phase 1 data. The company also reported its Q4 and Full Year 2025 financial results on March 5, 2026, highlighting strong execution in advancing its CAR-T cell therapy programs. Overall, the stock price decreased by 20.38% in the past month and 23.78% over the last three months.